Chemicals - Specialty
Compare Stocks
5 / 10Stock Comparison
GEVO vs VERO vs AMTX vs REX vs GPRE
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Oil & Gas Refining & Marketing
Chemicals - Specialty
Chemicals - Specialty
GEVO vs VERO vs AMTX vs REX vs GPRE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Chemicals - Specialty | Medical - Devices | Oil & Gas Refining & Marketing | Chemicals - Specialty | Chemicals - Specialty |
| Market Cap | $493M | $499K | $213M | $1.60B | $1.15B |
| Revenue (TTM) | $174M | $59M | $209M | $651M | $1.94B |
| Net Income (TTM) | $-11M | $-55M | $-74M | $50M | $-15M |
| Gross Margin | 23.4% | 64.4% | 3.4% | 12.7% | 1.8% |
| Operating Margin | -4.6% | -59.0% | -13.4% | 8.6% | 1.2% |
| Forward P/E | — | — | — | 62.8x | 46.6x |
| Total Debt | $168M | $43M | $318M | $21M | $508M |
| Cash & Equiv. | $1M | $4M | $5M | $196M | $182M |
GEVO vs VERO vs AMTX vs REX vs GPRE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Gevo, Inc. (GEVO) | 100 | 157.4 | +57.4% |
| Venus Concept Inc. (VERO) | 100 | 0.1 | -99.9% |
| Aemetis, Inc. (AMTX) | 100 | 390.0 | +290.0% |
| REX American Resour… (REX) | 100 | 498.3 | +398.3% |
| Green Plains Inc. (GPRE) | 100 | 192.5 | +92.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GEVO vs VERO vs AMTX vs REX vs GPRE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
GEVO ranks third and is worth considering specifically for growth exposure.
- Rev growth 8.5%, EPS growth 58.8%, 3Y rev CAGR 415.1%
- 8.5% revenue growth vs REX's -22.9%
VERO lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, AMTX doesn't own a clear edge in any measured category.
REX carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.36
- 464.7% 10Y total return vs GPRE's 21.3%
- Lower volatility, beta 0.36, Low D/E 3.3%, current ratio 8.64x
- Beta 0.36, current ratio 8.64x
GPRE is the #2 pick in this set and the best alternative if value and momentum is your priority.
- Lower P/E (46.6x vs 62.8x)
- +336.6% vs VERO's -88.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.5% revenue growth vs REX's -22.9% | |
| Value | Lower P/E (46.6x vs 62.8x) | |
| Quality / Margins | 7.7% margin vs VERO's -92.8% | |
| Stability / Safety | Beta 0.36 vs GEVO's 1.64, lower leverage | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +336.6% vs VERO's -88.5% | |
| Efficiency (ROA) | 6.7% ROA vs VERO's -88.6%, ROIC 11.4% vs -39.8% |
GEVO vs VERO vs AMTX vs REX vs GPRE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
GEVO vs VERO vs AMTX vs REX vs GPRE — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
REX leads in 3 of 6 categories
VERO leads 1 • GEVO leads 0 • AMTX leads 0 • GPRE leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — REX and GPRE each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
GPRE is the larger business by revenue, generating $1.9B annually — 32.9x VERO's $59M. REX is the more profitable business, keeping 7.7% of every revenue dollar as net income compared to VERO's -92.8%. On growth, GEVO holds the edge at +47.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $174M | $59M | $209M | $651M | $1.9B |
| EBITDAEarnings before interest/tax | $18M | -$31M | -$21M | $67M | $122M |
| Net IncomeAfter-tax profit | -$11M | -$55M | -$74M | $50M | -$15M |
| Free Cash FlowCash after capex | -$35M | -$21M | -$38M | $18M | $90M |
| Gross MarginGross profit ÷ Revenue | +23.4% | +64.4% | +3.4% | +12.7% | +1.8% |
| Operating MarginEBIT ÷ Revenue | -4.6% | -59.0% | -13.4% | +8.6% | +1.2% |
| Net MarginNet income ÷ Revenue | -6.6% | -92.8% | -35.4% | +7.7% | -0.8% |
| FCF MarginFCF ÷ Revenue | -19.9% | -35.2% | -18.2% | +2.7% | +4.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +47.5% | -8.2% | +27.4% | +0.4% | -25.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.8% | -8.5% | +29.8% | +2.9% | +134.2% |
Valuation Metrics
VERO leads this category, winning 2 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, REX's 16.6x EV/EBITDA is more attractive than GPRE's 103.8x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $493M | $498,989 | $213M | $1.6B | $1.1B |
| Enterprise ValueMkt cap + debt − cash | $659M | $39M | $526M | $1.4B | $1.5B |
| Trailing P/EPrice ÷ TTM EPS | -14.50x | -0.00x | -2.44x | 29.50x | -9.14x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 62.81x | 46.62x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.55x | — |
| EV / EBITDAEnterprise value multiple | 102.12x | — | — | 16.60x | 103.82x |
| Price / SalesMarket cap ÷ Revenue | 3.07x | 0.01x | 1.02x | 2.50x | 0.55x |
| Price / BookPrice ÷ Book value/share | 1.01x | 0.07x | — | 2.67x | 1.44x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | 17.84x |
Profitability & Efficiency
REX leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
REX delivers a 7.7% return on equity — every $100 of shareholder capital generates $8 in annual profit, vs $-17 for VERO. REX carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to VERO's 15.16x. On the Piotroski fundamental quality scale (0–9), VERO scores 5/9 vs GPRE's 4/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.4% | -17.4% | — | +7.7% | -2.0% |
| ROA (TTM)Return on assets | -1.7% | -88.6% | -29.3% | +6.7% | -1.0% |
| ROICReturn on invested capital | -2.8% | -39.8% | -70.3% | +11.4% | -5.2% |
| ROCEReturn on capital employed | -3.1% | -54.2% | -19.0% | +10.1% | -6.2% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 | 4 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.36x | 15.16x | — | 0.03x | 0.66x |
| Net DebtTotal debt minus cash | $166M | $39M | $313M | -$175M | $326M |
| Cash & Equiv.Liquid assets | $1M | $4M | $5M | $196M | $182M |
| Total DebtShort + long-term debt | $168M | $43M | $318M | $21M | $508M |
| Interest CoverageEBIT ÷ Interest expense | -0.04x | -9.69x | -0.27x | — | -0.08x |
Total Returns (Dividends Reinvested)
REX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in REX five years ago would be worth $34,996 today (with dividends reinvested), compared to $9 for VERO. Over the past 12 months, GPRE leads with a +336.6% total return vs VERO's -88.5%. The 3-year compound annual growth rate (CAGR) favors REX at 50.8% vs VERO's -79.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -1.5% | -82.3% | +96.2% | +50.2% | +60.1% |
| 1-Year ReturnPast 12 months | +88.0% | -88.5% | +140.0% | +147.6% | +336.6% |
| 3-Year ReturnCumulative with dividends | +65.0% | -99.1% | +37.4% | +243.1% | -46.8% |
| 5-Year ReturnCumulative with dividends | -65.2% | -99.9% | -76.1% | +250.0% | -48.5% |
| 10-Year ReturnCumulative with dividends | -98.6% | -100.0% | +31.1% | +464.7% | +21.3% |
| CAGR (3Y)Annualised 3-year return | +18.2% | -79.4% | +11.2% | +50.8% | -19.0% |
Risk & Volatility
REX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
REX is the less volatile stock with a 0.36 beta — it tends to amplify market swings less than GEVO's 1.64 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. REX currently trades 91.2% from its 52-week high vs VERO's 2.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.64x | 1.43x | 1.46x | 0.36x | 1.22x |
| 52-Week HighHighest price in past year | $2.97 | $12.93 | $3.80 | $53.36 | $18.94 |
| 52-Week LowLowest price in past year | $1.01 | $0.26 | $1.22 | $19.44 | $3.39 |
| % of 52W HighCurrent price vs 52-week peak | +68.4% | +2.1% | +82.1% | +91.2% | +86.9% |
| RSI (14)Momentum oscillator 0–100 | 53.5 | 42.9 | 58.2 | 59.1 | 54.3 |
| Avg Volume (50D)Average daily shares traded | 4.5M | 9K | 1.8M | 204K | 1.5M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: GEVO as "Buy", AMTX as "Buy", REX as "Buy", GPRE as "Buy". Consensus price targets imply 72.4% upside for GEVO (target: $4) vs -43.9% for AMTX (target: $2).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $3.50 | — | $1.75 | $60.00 | $13.80 |
| # AnalystsCovering analysts | 14 | — | 7 | 3 | 20 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — | 0 |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +0.9% | +2.6% |
REX leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). VERO leads in 1 (Valuation Metrics). 1 tied.
GEVO vs VERO vs AMTX vs REX vs GPRE: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is GEVO or VERO or AMTX or REX or GPRE a better buy right now?
For growth investors, Gevo, Inc.
(GEVO) is the stronger pick with 849. 3% revenue growth year-over-year, versus -22. 9% for REX American Resources Corporation (REX). REX American Resources Corporation (REX) offers the better valuation at 29. 5x trailing P/E (62. 8x forward), making it the more compelling value choice. Analysts rate Gevo, Inc. (GEVO) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — GEVO or VERO or AMTX or REX or GPRE?
On forward P/E, Green Plains Inc.
is actually cheaper at 46. 6x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — GEVO or VERO or AMTX or REX or GPRE?
Over the past 5 years, REX American Resources Corporation (REX) delivered a total return of +250.
0%, compared to -99. 9% for Venus Concept Inc. (VERO). Over 10 years, the gap is even starker: REX returned +464. 7% versus VERO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — GEVO or VERO or AMTX or REX or GPRE?
By beta (market sensitivity over 5 years), REX American Resources Corporation (REX) is the lower-risk stock at 0.
36β versus Gevo, Inc. 's 1. 64β — meaning GEVO is approximately 352% more volatile than REX relative to the S&P 500. On balance sheet safety, REX American Resources Corporation (REX) carries a lower debt/equity ratio of 3% versus 15% for Venus Concept Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — GEVO or VERO or AMTX or REX or GPRE?
By revenue growth (latest reported year), Gevo, Inc.
(GEVO) is pulling ahead at 849. 3% versus -22. 9% for REX American Resources Corporation (REX). On earnings-per-share growth, the picture is similar: Gevo, Inc. grew EPS 58. 8% year-over-year, compared to -869. 0% for Venus Concept Inc.. Over a 3-year CAGR, GEVO leads at 415. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — GEVO or VERO or AMTX or REX or GPRE?
REX American Resources Corporation (REX) is the more profitable company, earning 9.
1% net margin versus -72. 5% for Venus Concept Inc. — meaning it keeps 9. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REX leads at 10. 0% versus -41. 9% for VERO. At the gross margin level — before operating expenses — VERO leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is GEVO or VERO or AMTX or REX or GPRE more undervalued right now?
On forward earnings alone, Green Plains Inc.
(GPRE) trades at 46. 6x forward P/E versus 62. 8x for REX American Resources Corporation — 16. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GEVO: 72. 4% to $3. 50.
08Which pays a better dividend — GEVO or VERO or AMTX or REX or GPRE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is GEVO or VERO or AMTX or REX or GPRE better for a retirement portfolio?
For long-horizon retirement investors, REX American Resources Corporation (REX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
36), +464. 7% 10Y return). Gevo, Inc. (GEVO) carries a higher beta of 1. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (REX: +464. 7%, GEVO: -98. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between GEVO and VERO and AMTX and REX and GPRE?
These companies operate in different sectors (GEVO (Basic Materials) and VERO (Healthcare) and AMTX (Energy) and REX (Basic Materials) and GPRE (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: GEVO is a small-cap high-growth stock; VERO is a small-cap quality compounder stock; AMTX is a small-cap quality compounder stock; REX is a small-cap quality compounder stock; GPRE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.